Skip to main content
. 2013 Mar 11;210(3):623–639. doi: 10.1084/jem.20121610

Figure 4.

Figure 4.

Blockade of TGFβ during recovery from myelotoxic stress prolongs HSPC cycling. (A) Flow cytometry gating strategy for cell cycle analysis of LKS+ (LincKit+Sca1+) and LKS + SLAM (LincKit+Sca1+CD48CD150+) cells is shown (top images show frequency in total BM; bottom images show percentage of LKS + SLAM gated cells). (B) Mice were treated with 5FU, and then with the TGFβ-neutralizing antibody, 1D11 (5FU-I), or the isotype control antibody 13C4 (5FU-C) on day 5, 7, and 9. The percentage of quiescent LKS+ cells is shown before treatment (D0) and at various times after treatment with 5FU and 1D11 (5FU-I, gray bars) or the control antibody (5FU-C, white bars; n = 5/group). (C) Cell cycle status of BM LKS + SLAM HSCs is shown before (D0) and on day 15 after treatment with 5FU and 1D11 (5FU-I) or the control antibody (n = 5). (D) Cohorts of untreated, homeostatic mice (n = 10) were administered either the TGFβ-neutralizing antibody 1D11 (I; 10 mg/kg) or control antibody 13C4 (C; 10 mg/kg) on days −3 and −1 before analysis on day 0. Bivariate cell cycle status of BM LKS + SLAM HSC on day 0 is shown. All quantified data are shown as mean ± SEM (*, P < 0.05; **, P < 0.01; ***, P < 0.001, or if undesignated, the comparison was not significant).